COMPASS Pathways plc (NASDAQ:CMPS) is among the Best Get Rich Fast Stocks to Buy Right Now. As of December 24, COMPASS Pathways plc (NASDAQ:CMPS) has a ‘Buy’ or equivalent rating from the majority of ...

Compass Pathways Limited (NASDAQ:CMPS), a pioneering force in the mental health care sector with a market capitalization of $287 million, is navigating a complex landscape as it develops its flagship ...

LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access to evidence-based ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first ...

Compass Pathways Plc (NASDAQ: CMPS) stock has reached a new 52-week low, touching down at $2.87, marking a 73% decline from its 52-week high of $10.31. According to InvestingPro data, the company ...

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

The trial is a phase IIb dose-ranging study with 216 patients taking part in 12 to 15 research sites across Europe and North America. It will begin in the UK later this month and sites in other ...

Compass Pathways Plc (NASDAQ: CMPS) stock has reached a new 52-week low, touching down at $3.85. This latest price point marks a significant downturn for the company, which specializes in mental ...

Compass Pathways, which has been navigating the challenges of the pharmaceutical industry, holds a market capitalization of $568.61 million. Despite a difficult period, the company maintains a ...

Open-label Phase 2 study shows a single 25 mg COMP360 psilocybin dose was well tolerated, with no serious adverse events observed, and indicated both rapid and durable improvement in symptoms from ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth ...

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial ...